Clinical trials: pills and oral medicines
Fibromyalgia, Myofascial Pain Syndromes
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study).
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases
- Trial name
- AFFIRM (NCT02436096)
- Testing
- TNX-102 SL Tablet, 2.8mg
- Where
- 35 sites in United States
- Volunteers
- 519 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Trial name
- SEARCH (NCT03992339)
- Testing
- ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
- Where
- 18 sites in China
- Volunteers
- 60 people
- Sponsor
- Antengene Corporation
Cirrhosis, Hepatic Encephalopathy
VE303 for Treatment of Hepatic Encephalopathy (HE)
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy.
- Trial name
- NCT04899115
- Testing
- VE303, oral vancomycin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Patricia Bloom
PTSD
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine.
- Trial name
- RECOVERY (NCT03841773)
- Testing
- TNX-102 SL
- Where
- 30 sites in United States
- Volunteers
- 192 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Type 2 Diabetes Treated With Insulin
Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
- Trial name
- NCT06473662
- Testing
- Oral insulin
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Roger New
Bladder Cancer
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer.
- Trial name
- NCT01489813
- Testing
- Genistein, Sugar pill
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Allergic Rhinitis Due to House Dust Mite
Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model
The purpose of this study is to assess the effect of 3 doses of sublingual house dust mite (HDM) tablets versus placebo in the change from baseline of rhinitis total symptom score during the allergen chamber challenge before and…
- Trial name
- NCT01527188
- Testing
- 100 IR house dust mites allergen extract tablet, 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Where
- Canada
- Volunteers
- 355 people
- Sponsor
- Stallergenes Greer
Anemia, Iron Deficiency Anemia
Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency (ID) and IDA can present with a multitude of symptoms including fatigue, restless legs syndrome and…
- Trial name
- DEODO (NCT03725384)
- Testing
- Ferrous Sulfate 300Mg Tablet, Vitamin C 500Mg tablet
- Where
- 2 sites in Canada
- Volunteers
- 51 people
- Sponsor
- Sunnybrook Health Sciences Centre
Osteoarthritis, Osteo Arthritis Knee
Colchicine for the Treatment of Osteoarthritis of the Knee
This prospective, double-blinded, placebo-controlled, randomized trial will enroll 120 SKOA subjects at the NYU Center for Musculoskeletal Care.
- Trial name
- CLOAK (NCT03913442)
- Testing
- Colchicine 0.8 mg or 0.6 mg orally once daily
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with…
- Trial name
- NCT04811040
- Testing
- Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab
- Where
- 23 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Opioid Substitution Treatment
ICE-T Pain Regimen for Total Laparoscopic Hysterectomy
The purpose of this randomized controlled trial is to determine whether, "ICE-T," a multimodal postoperative pain regimen composed of around the clock ice packs, toradol, and tylenol, has improved pain control compared to the…
- Trial name
- NCT03987022
- Testing
- Ketorolac, Opioids, Ice Packs
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- MetroHealth Medical Center
Fibromyalgia
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RESILIENT (NCT05273749)
- Testing
- TNX-102 SL Tablet, 5.6 mg
- Where
- 33 sites in United States
- Volunteers
- 457 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Allergy
A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree…
- Trial name
- TreeTop (NCT04878354)
- Testing
- Tree SLIT-tablet
- Where
- 80 sites in Austria, Belgium and 9 more
- Volunteers
- 952 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to House Dust Mite
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
The purpose of this study is to investigate the safety and tolerability of different doses of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust mite-associated allergic rhinitis.
- Trial name
- NCT01919554
- Testing
- 500 IR house dust mites allergen extract tablet, 1000 IR house dust mites allergen extract tablet, 1500 IR house dust mites allergen extract tablet
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Stallergenes Greer
Immune Thrombocytopenia
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
- Trial name
- NCT04638829
- Testing
- Avatrombopag Oral Tablet
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sobi, Inc.
Diabetes Mellitus
Study of Harmine in Healthy Subjects
The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.
- Trial name
- NCT05526430
- Testing
- Harmine Hydrochloride Capsules
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- James Murrough
Hemodynamics, Cardiovascular System
Cardiovascular Effects of Adderall in Healthy Adults.
This study is designed to investigate the cardiovascular response (blood pressure, heart rate, electrocardiographic response and blood vessel reactivity response) to taking Adderall in healthy adults.
- Trial name
- NCT02979327
- Testing
- Adderall capsule
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Invasive Aspergillosis
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).
- Trial name
- NCT04218851
- Testing
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Where
- 29 sites in United States, Belgium and 8 more
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01651000
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- OPKO IP Holdings II, Inc.
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.